Pancreatic cancer risk in hepatitis C virus infection in the era of Direct Acting Antiretroviral Agents (DAAs) | ||||
| Microbes and Infectious Diseases | ||||
| Articles in Press, Accepted Manuscript, Available Online from 30 August 2025 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mid.2025.411934.3092 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
lamiaa Fadel Alkilany  1; Rania Bakry2; M.A. salem3; Engy Adel Shafik2; shaza Fadel Alkilany4; ayat Mohamed Sayed5; Aml Ali Aboelghait6; Doaa A. Mohammed2
| ||||
| 1Virology and Immunology Unit, Cancer Biology Department, South Egypt Cancer Institute, Assiut University, Egypt | ||||
| 2Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Egypt | ||||
| 3Surgical Oncology Department, South Egypt Cancer Institute, Assiut University, Egypt | ||||
| 4Public Health and Community Medicine Department, Faculty of Medicine, Minia University, Egypt | ||||
| 5Medical Oncology and Hematological Malignancy Department, South Egypt Cancer Institute, Assiut University, Egypt | ||||
| 6Internal medicine and Endocrinology Department, Faculty of medicine Assiut University, Egypt | ||||
| Abstract | ||||
| Background: Egypt used to be the country with the highest prevalence of hepatitis C virus (HCV) infection in the world. But now it is on the way to eliminate HCV by the efforts national Egyptian campaign programs to treat population by direct acting antiretroviral therapy (DAAs). HCV was found to be related to many extra hepatic malignancies like pancreatic cancer. In the era of DAAs, it was expected to find a drop in hepatocellular carcinoma (HCC) cases, but controversial results were found about the role of DAAs in changing cancer risk in chronic hepatitis C (CHC) patients. Limited data is available about DAAs role in extrahepatic malignancy risk. Methods: This is a retrospective case control study that included 76 pancreatic cancer patients admitted to medical oncology department in the period (2023 -2024) and 100 age and sex matched controls. Patients were serologically tested for HCV and HBV and results were confirmed by PCR. Patients are grouped according to the history of DAAs treatment. Results: Untreated HCV patients showed 3.5 fold increase in pancreatic cancer risk than HCV negative controls (p value 0.028). Patients who were treated from CHC by DAAs and achieved sustained virological response had no significant increase in pancreatic cancer risk. Patients with liver cirrhosis showed 7.1 fold increase in pancreatic cancer risk (p value 0.032). Conclusion: CHC is significantly associated with pancreatic cancer but treatment of chronic hepatitis C virus with DAAs was not associated with increase in pancreatic cancer risk. | ||||
| Keywords | ||||
| Pancreatic cancer; hepatitis C virus; Direct Acting Antiretrovirals | ||||
|
Statistics Article View: 6 |
||||
